Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16225213 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4TACR1MRGPRX1MGLL | |
| SCHEMBL2807019 | 0.76 | SLC6A2 (0.43) | SLC6A2SLC6A4TACR1MRGPRX1MGLL | |
| SCHEMBL27331494 | 0.74 | IDO1 (1.00) | IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4387326 | 0.72 | IDO1 (0.57) | IDO1EPHX1 | |
| SCHEMBL5272005 | 0.71 | TACR1 (0.41) | SLC6A2SLC6A4TACR1MRGPRX1MGLL | |
| SCHEMBL2939744 | 0.70 | GRM4 (0.44) | IDO1SLC6A2SLC6A4DRD2DRD3 | |
| SCHEMBL13589661 | 0.70 | S1PR1 (0.41) | — | |
| SCHEMBL15564047 | 0.70 | SLC6A2 (0.39) | SLC6A2SLC6A4TACR1MRGPRX1MGLL | |
| SCHEMBL4083138 | 0.69 | ENPP2 (0.47) | IDO1SLC6A2SLC6A4DRD2DRD3 | |
| SCHEMBL4380343 | 0.69 | S1PR1 (0.38) | TACR1MRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885SLC6A2 1326/4885SLC6A4 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.